Cannabis plant. Source: ECS Botanics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ECS Botanics (ECS) secures supply agreement with Australian cannabis company Canngea
  • The one-year rolling agreement is for the supply of medicinal cannabis products and is tipped to bring in revenue of $410,000 per year for ECS
  • The first dispatch of medical cannabis is expected in October and will include dry flowers and oils
  • ECS says the deal validates the growing market in Australia as well as the company’s business model
  • Shares is trading 5.9 per cent higher at 3.6 cents at 12:14pm AEST

ECS Botanics (ECS) has secured a supply agreement with Australian cannabis company Canngea.

ECS is a medicinal cannabis and industrial hemp business with farms and facilities in Tasmania and Victoria for cultivation, processing and manufacturing needs.

Canngea was established in 2017 and focuses on distributing a range of solutions to both international and domestic markets.

The one-year rolling agreement is for the supply of medicinal cannabis products and is tipped to bring in revenue of $410,000 per year for ECS.

The first dispatch of medical cannabis is expected in October and will include dry flowers and oils.

Both parties are able to terminate the agreement following a material breach which can’t be remedied within 20 business days, or either company enters a state of insolvency or liquidation.

ECS said the deal validates the growing market in Australia as well as the company’s business model.

Commenting on the agreement, Canngea’s Managing Director Ryan Ballantyne said working with ECS is key to enhancing local supply capabilities for its existing clients.

“Collaborations like this strengthen the ability of the Australian medicinal
cannabis industry to service growing demand for safe, high-quality, and affordable products.”

ECS is encouraged by market demand for medical cannabis products and said it continues to build a strong sales pipeline with the aim of significantly increasing the scale of cannabis production.

Additionally, the company said other contracts are in the final stages and it will update the market accordingly.

Shares were trading 5.9 per cent higher at 3.6 cents at 12:14pm AEST.

ecs by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…